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Introduction 
The diagnostic use of neuroimaging has increased in the past twenty years. Different imaging 
techniques are widely available such as computed tomography, positron emission tomography 
and magnetic resonance imaging (MRI)(1). Neuroimaging can evaluate the early development, 
ageing and pathological stages of the central nervous system (CNS) and monitor changes 
during and after treatment (2-4). MRI became an important approach in neuroscience research 
as well as clinical applications, due to many advantages such as wide spectrum of MRI methods 
used with different out comes such as strucural and diffusional methods (5), and the ability to 
visualize non-invasively anatomical structures of the brain or their functional state(6). Since 
the brain consists of approximately 70 % of water, motion of water throughout the tissues 
provides an important insight into brain microstructure. The characteristics of diffusion are 
often associated with the structural organization of tissues. Therefore, one rapidly developing 
field of MRI based on the water diffusion detection is diffusion weighted imaging (DWI). This 
technique was introduced fifty years ago when diffusional changes were reported for the first 
time (7). DWI is a unique MRI technique which maps water motion at microstructural level 
and it is able to differentiate between normal and abnormal water diffusion in biological tissues 
(8). DWI considers water motion free in any direction with no hindrance, i.e. isotropic 
diffusion. DWI is widely used in clinical fields, in diagnosis of acute ischemic stroke, traumatic 
brain injury and inflammation (9, 10). However, all biological systems are complex structures 
with a variety of barriers restricting the water diffusion and leading to directional water 
movement. This process is called anisotropic diffusion (8).  
 
Physical theory of the diffusion weighted imaging 
Diffusion is a mass transport, a random movement of molecules or particles (which do not 
require bulk motion) (11, 12). An approach to diffusion was undertaken by Einstein and 
Smoluchowski, they proposed a displacement distribution parameter describing the mean 
squared displacement of the particles in timeframe (13). 
< 𝑥2 >= 2𝐷∆  
where D is diffusion coefficient, <x2> is the mean squared displacement during a diffusion 
time Δ. In three-dimension, the equation has a form: 
< 𝑟2 > = 6𝐷𝑡  
where <r2> is the mean squared displacement in 3D. The distribution of squared displacements 
takes a Gaussian form (see Figure 1). Any MR imaging technique can be designed to be 
sensitive to diffusion by adding magnetic fields gradients. It is possible, with the usage of 
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diffusion-sensitizing gradients in any direction (see Figure 2). Diffusion imaging provides an 
estimate of D in each voxel from a series of DWI obtained with gradients applied in one 
direction. Spins that are moving along the direction of the applied gradient diphase and, 
consequently, decrease of the signal, which can be represented with a mono-exponential signal 
decay equation: 
𝑆 = 𝑆0 𝑒
−𝑏𝐷  
thus: 
ln
𝑆
𝑆0
= −𝑏𝐷  
where S is the measured signal, S0 is the signal measured without diffusion gradient (b = 0) 
and b (s/mm2) is the measure of diffusion encoding in the diffusion gradients: 
𝑏 =  ϒ2𝛿2|𝐺|2 (𝛥 − 
𝛿
3
)  
where ϒ is the gyromagnetic ratio, δ is the duration of the diffusion pulse, |G| is amplitude of 
the diffusion gradient and Δ is time interval between two diffusion gradients (Figure 2). 
Parameter is called a b-value, which is a factor that reflects the strength and timing of the 
gradients used in diffusion-weighted images.  
It is known that a tissue is characterized with anisotropic diffusion due to membranes or cell 
wall. This argument imposes diffusion coefficient to be characterized with the 2nd order 
diffusion tensor (3 x 3 matrix): 
𝑫 = (
𝐷𝑥𝑥 𝐷𝑥𝑦 𝐷𝑥𝑧
𝐷𝑦𝑥 𝐷𝑦𝑦 𝐷𝑦𝑧
𝐷𝑧𝑥 𝐷𝑧𝑦 𝐷𝑧𝑧
)  
where Dxx, Dxy … represents different diffusion rates along given direction. D is positive 
definite and symmetric. Diffusion tensor can be represented as a triaxle ellipsoid in the 
reference frame of the eigenvectors (11, 14), which simplified scheme is presented on Figure 3. 
This model simplifies to isotropic model when diagonal elements are equal Dxx + Dyy + Dzz = 
D and off-diagonal elements equal zero.  
DTI assumes that diffusion can be described by a tensor and was developed to describe 
anisotropic diffusion (11). Here, minimum six gradient directions and two b-values are needed 
to calculate DTI map from tensors (tensor has 32 = 9 components and 6 are independent). In 
this modality the most clinically useful measure obtained from DTI are MD and anisotropy 
indices characterized by FA or relative anisotropy (RA) (12). MD is represented as: 
𝑀𝐷 =< 𝐷 > =
𝐷𝑥𝑥+𝐷𝑦𝑦+𝐷𝑧𝑧
3
=
𝜆𝑥𝑥+𝜆𝑦𝑦+𝜆𝑧𝑧
3
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and is linked with tissue integrity (white and grey matter). The most common parameter used 
is FA, which normalizes the variance by the magnitude of the tensor as a whole:  
𝐹𝐴 =  √
3
2
(𝐷𝑥𝑥−< 𝐷 >)2 + (𝐷𝑦𝑦−< 𝐷 >)2 + (𝐷𝑧𝑧−< 𝐷 >)2
𝐷𝑥𝑥2 + 𝐷𝑦𝑦2 + 𝐷𝑧𝑧2
  
FA describes the fraction of the tensor that can be assigned to anisotropic diffusion, thus shows 
regions where diffusion is most directional (describes integrity of the WM fiber bundles) (11, 
15, 16). Another handy representation is given by principal diffusion directions such as AD 
and RD, which are defined below: 
𝐴𝐷 =  𝐷𝑥𝑥, 𝑅𝐷 =  
𝐷𝑦𝑦 + 𝐷𝑧𝑧
2
  
AD and RD can identify axonal injuries or demyelination (17) An extension of DTI model, 
called DKI is described. It was introduced in 2005 and since then, many theoretical papers 
demonstrated its complementary value to DTI (18, 19). This model assumes that water 
diffusion in biological systems has a non-Gaussian behavior. In statistic, kurtosis is a 
parameter, which describes peakedness of a probability of water distribution (see Figure 1). 
Higher values of kurtosis assume more complex environment and aberrations to normal 
diffusion. In DKI model logarithmic signal loss can be described as:  
ln
𝑆
𝑆0
= −𝑏𝐷𝑎𝑝𝑝 +  
1
6
𝑏2𝐷𝑎𝑝𝑝
2𝐾𝑎𝑝𝑝  
where K is kurtosis. Kurtosis is related to the 4th order tensor (3 x 3 x 3 x 3). 
Kurtosis tensor (K) has complex form and geometrically kurtosis cannot be represented as an 
ellipsoid. 
The higher the kurtosis, the more the water molecule diffusion deviates from Gaussian 
distribution pointing at more restricted diffusion environment. The most practical parameters 
are MK, AK and RK. 
𝑀𝐾 =  
1
𝑛
∑ 𝐾𝑖
𝑛
𝑖=1
, 𝐴𝐾 =  𝐾1 , 𝑅𝐾 =  
𝐾2 + 𝐾3
2
 
MK is defined as the kurtosis averaged among all directions. Respectively, FA is defined as: 
𝐹𝐴𝐾 =  √
3
2
(𝐾1 − ?̅?)2 + (𝐾2 − ?̅?)2 + (𝐾3 − ?̅?)2
𝐾1
2 + 𝐾2
2 + 𝐾3
2 , ?̅? =  
1
3
 ∑ 𝐾𝑖
3
𝑖=1
 
 
The DKI method requires data acquisitions with several (minimally three) b-values (with b-
value usually larger than 1000 s/mm2) and at least 15 directions of diffusion gradient (18). The 
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mono-exponential model DTI is valid only for small b-values (Figure 3). When larger b-values 
are used (larger than 1000 s/mm2) the method is sensitive to shorter molecular distances 
showing deviation from DTI mono-exponential model and allows probing regions with larger 
diffusion restrictions. A simple illustration associated with DTI and DKI models is presented 
on Figure 4. The main limitation in DTI is the strict dependence of the results (e.g. values of 
MD or FA) on the used b-values, which can lead to misinterpretation of the results. In DKI, 
restricted diffusion can be investigated when high b-values are used, even values 800 – 15000 
s/mm2 probing 1 – 2 μm molecule distances and diffusion of order of 50 – 100 ms (14). 
Additionally, in some studies data were acquired for many diffusion directions, up to 100 (2), 
yet, such large number of gradient directions imposes longer measurement as brain images are 
repeated multiplied by the number of used b-values. Longer scanning has to be taken under 
consideration especially in terms of motion artefacts caused by subject’s movement in the 
scanner.  
 
Diffusion tensor imaging (DTI) 
The biological organized structure of the CNS including myelinated axons, unmyelinated 
axons, cellular membrane, presence of proteins and intracellular organelles affect the water 
diffusion inside the CNS. This factors could divide the water diffusion in CNS into two types, 
isotropic diffusion in which water diffusion is equal in all directions and is observed in 
cerebrospinal fluid and grey matter. The second type is anisotropic diffusion, in which water 
diffusion is mostly unidirectional and is observed in white matter. This technique that accounts 
for anisotropic directionality is called DTI. It describes the magnitude of the water diffusion in 
three dimensions and characterizes the directionality of water movement in fibrous tissues 
showing their architecture (20). DTI considers that the water diffusion in each voxel follows 
Gaussian distribution (21, 22). According to this assumption a biological system is similar to a 
bucket of water without diffusion hindrance (23). However, brain tissues are much more 
complex and in truth water diffusion is hindered by cell membrane, cell constituents and it 
follows non – Gaussian distribution. This is important especially in white matter (WM) where 
myelinated and unmyelinated axons represent highly fibrous structures rendering the diffusion 
anisotropic (24). Specifically, water diffusion in WM is relatively unrestricted parallel to the 
fiber (axonal) orientation while it is highly restricted in the perpendicular direction (24). Gray 
matter (GM) which consists mainly of neuronal cell bodies where diffusion is more isotropic, 
so water diffusion unlike WM is unrestricted in all directions (25). However, majority of the 
studies used fractional anisotropy (FA) as the main DTI metric. FA measures the degree of the 
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diffusional anisotropy in the brain tissue such as the extent of differences among the three 
directions. FA is a derived value and has a range between 0.1 and 1. The increase of FA values 
reflects directional coherence or diffusion restriction, which means that the extent of diffusion 
in one direction. However, the exact biological processes leading to changes in the diffusivity 
parameter are still unknown. Lower FA might be associated with changes in intrinsic properties 
of a fiber or changes due to the presence of more than one fiber in a voxel. FA fails to detect 
changes in the gray matter (GM), because the diffusivity is more isotropic, i.e. water diffuses 
almost freely in all directions, while FA is more sensitive in directionally oriented structures 
like in WM (18, 21). Thus, validity of the DTI results is limited in GM, while it allows to 
distinguish between normal and pathological state of the WM. More directionally specific DTI 
metrics: axial diffusivity (AD), radial diffusivity (RD) and mean diffusivity (MD), which 
distinguished by direction. AD measures the extent of diffusion occurring in parallel direction 
with the fiber and it can be altered by deterioration of the axonal integrity (26). RD reflects the 
extent of diffusion occurring perpendicular to the fiber and therefore RD has an inverse relation 
with the myelin integrity degeneration (26). MD is the mean of AD and RD describing the 
magnitude of the diffusion.  
DTI has been applied in a wide range of clinical and preclinical research studies of CNS and 
increase the high light on this method for diagnosis of neurodegenerative processes such as 
multiple sclerosis (27, 28), Alzheimer’s disease (29, 30) and Parkinson’s disease (31) or other 
diseases such as stroke (32) and traumatic brain injury (33).  
 
Diffusion kurtosis imaging (DKI) 
DTI considers the diffusion of water in brain as Gaussian distribution, hence it is unable to 
detect the diffusion heterogeneity in biological tissues. Therefore, DKI technique was 
introduced as a mathematical extension of DTI. Kurtosis is described as a dimensionless 
measure which quantifies the non-Gaussian distribution of water diffusion in a voxel (18, 21). 
Thus, DKI also considers the voxel in the biological system as a bucket of water but with 
diffusional hindrance arising from multiple tissue compartments, thus it detects restriction of 
the water diffusion in isotropic as well as anisotropic environment of each voxel according to 
the degree of restriction such as protein accumulation, while FA is able to detect the restriction 
of water diffusion only in the anisotropic environment (23). DKI provides not only the diffusion 
tensor metrics (AD, RD, MD, and FA) but also the kurtosis metrics: axial kurtosis (AK), radial 
kurtosis (RK), and mean kurtosis (MK). The higher the kurtosis value the more restrictions of 
the normal diffusion inside each voxel wether there is some factors that affects the water 
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diffusion even if it is not an anisotropic enviroment, unlike FA which consider the extent of 
diffusion in one direction which can be seen in the anisotropic environment only. This can be 
caused by different factors, e.g. pathological protein accumulation or iron deposition while 
decrease of kurtosis could be a sign of neuronal loss. Thus, DKI is sensitive in detecting 
pathology in the GM (34) as well as in WM (35). Therefore, the importance of DKI comes 
from the ability to detect the anisotropic as well as the isotropic diffusion. This supports the 
possibility that DKI might become a sensitive early stage biomarker for many 
neurodegenerative disorders.  
 
Preclinical and clinical applications of DKI  
Parkinson’s disease  
Parkinson’s disease (PD) is the second most common progressive neurodegenerative disorder 
characteristic by motor symptoms represented by bradykinesia, resting tremor, muscle rigidity 
and gait problems. The PD patients also suffer numerous non-motor symptoms including 
cognitive dysfunction, sleep disorders, psychiatric comorbidities, olfactory and gastrointestinal 
dysfunctions (36). Furthermore, motor PD symptoms start when 50-70 % of dopaminergic 
projections from substantia nigra (SN) to striatum are lost, i.e. at a very late stage of the 
neurodegenerative process. PD neuropathology progression involves multiple processes, 
including intracytoplasmic abnormal aggregation of protein in neurons called Lewy bodies, 
which are mainly consist of α-synuclein and ubiquitin (37, 38). α-synuclein is a protein which 
is found pre-synaptic ally, the accumulation of α-synuclein induce the formation of toxic 
oligomeric protein which can activate the immune system and lead to degeneration of the 
neurons (39). The etiology of PD remains to be elucidated and many factors such as aging, 
environmental and genetics contribute the neurodegeneration in PD, diffusion weighted MRI 
techniques may be able to efficiently track the pathological process.  
Many theories were postulated to explain the mechanism behind neuronal loss, such as 
oxidative stress, rise of iron content, pathological protein accumulation and neuroinflammation 
(40, 41). One theory which describes the origin of idiopathic PD is the Braak’s theory. It 
postulates that PD starts when α-synuclein accumulation initiates through olfactory bulbs, 
dorsal motor nucleus of the glossopharyngeal vagal nerve. Then, at the second stage α-
synuclein accumulation spreads through the brain regions such as brain stem, medulla 
oblongata which may develop the non-motor symptoms such as cognitive dysfunction and 
depression and when the pathology reaches SN the motor symptoms start to appear. (38). In 
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the later stages the accumulation spreads to more brain regions such as the striatum and cortex 
(39, 42).  
Hitherto the treatment of PD is based on increasing the level of dopamine which does not stop 
the protein accumulation neither the neurodegeneration process. Thus, the development of 
reliable early stage diagnosis may help in the development of neuroprotective treatments, 
which are needed to halt or slow the PD progression when patients might still be eligible for 
neuroprotective treatment (43, 44). DKI seems to be a promising candidate and both clinical 
and preclinical studies are currently trying to evaluate its relevance as such biomarker.  
 
Clinical studies 
Several DTI studies in PD patients have demonstrated that FA is reduced in SN at both early 
and late stage of PD (45, 46). Furthermore, DTI detected a decrease in FA and increase of 
diffusivity caused the olfactory dysfunction which might be one of the initial phases of PD (47, 
48). However, DTI sensitivity is limited to detect only the anisotropic diffusivity changes that 
is relevant only in the WM. Therefore, several clinical studies used DKI in PD patients in order 
to detect the changes in both WM and GM.  
Wang et al.(49) were the first to find a significant increase in MK in caudate nucleus, putamen, 
globus pallidus and SN in the early to middle stage of PD and suggested that MK reflects the 
presence PD pathology rather than the stage of disease. However, they admitted that the 
explanation of MK changes in basal ganglia of PD patients is yet unknown. Unfortunately, AK 
and RK data were not evaluated in this study. However, the results of AK and RK may provide 
more information about the mechanisms underlying the DKI changes in PD patients (49). The 
first to apply DKI on WM of PD patients was Kamagata et al., in two different studies. In the 
first study MK and FA were found to be decreased in anterior cingulum in PD patients while 
MK gave the best diagnostic performance. Importantly, the authors claimed that anterior 
cingulum is the part of brain that shows a pathological alteration at early stage and MK in this 
region may be useful as a PD diagnostic biomarker (50). Furthermore, the same team used 
tract-based spatial statistics analysis which identifies the core of the WM bundles and with this 
method alteration of diffusivity parameters can be detected for evaluation of MK of the whole 
brain (51), MK was reduced in frontal WM, corpus callosum, parietal, occipital, and right 
temporal lobe and by analyzing the crossing fibers areas, MK was also reduced in PD patients 
in posterior corona radiata and superior longitudinal fascicle (52).  
The most recent study by Zhang et al (53), assessed DKI in the SN and compared the sensitivity 
of MK over FA in this region. A significant increase in MK and decrease in FA were found in 
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this study (53), they concluded that MK results goes in line with Wang et al. (49) the only study 
concerning DKI in SN of PD patients. Also FA decrease is consistent with other clinical 
foundations in the same brain region (54, 55). Based on the previous studies MK found to be 
increased in GM and decreased in WM in different brain region of PD patients. In conclusion, 
based on the results from clinical studies MK seems to be able to help the clinical diagnosis 
due to the detection of early changes in PD, especially in the SN. Unfortunately, there is no 
data out of other DKI matrices such as AK, RK and their diagnostic value is currently unknown. 
 
Preclinical studies 
Just like in case of the clinical studies, there are only a limited number of studies on PD-like 
animal models reporting DTI and DKI findings. So far, three different studies used 
pharmacological models of PD-like neurodegeneration, specifically – MPTP (1-methyl-4-
phenyl-1, 2, 3, 6-tetrahydropyridine) treated mice, and 6-hydroxydopamine (6-OHDA) 
lesioned rats. DTI results demonstrated a reduction of FA in SN, which goes in line with the 
DTI clinical studies (56, 57). A recent study used marmosets treated with MPTP to study the 
nigrostriatal pathway. MD was increased in the right and AD in the left side while RD was 
increased in both sides of the nigrostriatal pathway. Interestingly no significant FA results were 
found in SN and the nigrostriatal pathway unlike the previous studies (58). However, as 
repeatedly pointed out, DTI results may not be valid enough in assessment of GM structures. 
Khairnar et al. were the first who applied DKI in a well-established transgenic mouse model 
of PD overexpressing human α-synuclein (TNWT-61) under the murine Thy-1 promoter (59). 
This model is characterized by accumulation of α-synuclein in almost all brain regions while 
there is no loss of neurons (60). DKI was measured in four different age groups. A young adult 
3 and 6 months old mice were used to represent the early stage of PD like disease. At this age 
DKI demonstrated an increase in MK in striatum and thalamus and RK increase in thalamus in 
both time-points while in the SN MK was significantly increased only at 6 months old 
transgenic animals. Furthermore, tract-based spatial statistics analysis recorded alterations in 
WM only at 6 months (61). The second study used adult 9 months old mice which are at the 
zenith of the α-synuclein pathology. In this report, MK demonstrated a significant increase in 
SN, striatum, sensorimotor cortex and thalamus. AK showed differences only in the striatum 
and thalamus, while RK showed difference only in thalamus. In the same study tract-based 
spatial statistics showed an increase in MK bilaterally in the external capsule, AK in left-sided 
external capsule, RK bilaterally in the external capsule, corpus callosum, cingulum, dorsal 
hippocampal commissure. The last study focused on the late stage of the pathology present in 
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very old mice at14 months of age. Consistently with the previous findings MK demonstrated 
an increase in SN, striatum, sensorimotor cortex, thalamus and this time also hippocampus.  
Considering all the above studies we can see certain pathological progression using the kurtosis 
metrics. Furthermore, unlike FA, kurtosis could show a remarkable result already in early 
stages of the PD-like pathology. Interestingly the MK increase in SN goes in line with the 
clinical findings which also found an increase in MK of SN (49, 53). Conversely, tract-based 
spatial statistics analysis found also increases in kurtosis metric in some WM regions which is 
not in line with clinical findings (50, 52). This discrepancy could be due to neurodegenerative 
process in PD which is not present in the transgenic animal model used in this study. Hence, 
α-synuclein accumulation could be the pathological process underlying the increase of kurtosis 
values while loss of neurons may cause the opposite result.  
Taken together, so far, there are no animal studies using DKI in another model than the 
transgenic TNWT-61 mice. The available reports found increases in kurtosis metrics at all-time 
points. Interestingly, the first regions showing enhanced MK already at 3 months of age were 
thalamus and striatum while in the SN the change become significant at 6 months. Overall, 
similarly as in the clinical trials, MK was the most sensitive readout and DKI seems to be more 
useful in detecting early PD brain pathology than DTI. 
 
Alzheimer’s disease (AlzD) 
AlzD is a progressive neurodegenerative disorder affecting cognitive functions and it is a 
common cause for dementia. Hitherto there is no curative treatment of AlzD (62). However, it 
was suggested that at early stage of the neurodegenerative process an innovative 
neuroprotective treatment may slow down or halt the progression of AlzD (63). Therefore, 
early diagnosis of AlzD is of paramount importance and it could also provide a better 
understanding of the microstructural changes and monitor therapeutic efficacy of new drugs.  
Mild cognitive impairment (MCI) believed to be the transitional phase between normal and 
AlzD patients (64). MCI is associated with development and progression of brain atrophy, 
inititation of apoptosis (activation of glial cells) and reduction of the neuronal volume (myelin 
and axonal loss) leading to changes in water diffusivity (65, 66). Protein accumulation is one 
of the early hallmark of AlzD characterized by hyper-phosphorylation of tau proteins which 
start to aggregate leading to neurofibrillary tangles formation inside the nerve cell bodies (67, 
68). This aggregation causes a collapse of neuronal connectivity and eventually cell death (69). 
Furthermore, the mutation of the genes encoding amyloid precursor protein and presenilin 1 
and 2 alters the synthesis of amyloid-β (Aβ42) the main component of senile plaques and cause 
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several familial forms of AlzD. Recent studies indicate that glial cells (e.g. astrocytes, 
oligodendrocytes) play an important role in neuronal connectivity and neuronal death in AlzD. 
Therefore, an early neuroimaging biomarker which can detect the pathological protein 
accumulation may be a useful tool to provide a precise early diagnosis of AlzD.  
 
Clinical studies  
Currently the diagnosis of AlzD by neuroimaging is widely used especially structural MRI 
because it is able to measure the volume of the brain especially the volume of hippocampus. 
Therefore, developing new MRI methods for early stage of interest for the diagnosis of AlzD, 
Numerous DTI has shown remarkable results in brain ageing and dementia studies, due to its 
ability to evaluate the WM alteration associated with the disease progression. However, the 
meta-analysis identified diffusivity read-outs more sensitive than FA (65). The first DKI study 
in AlzD patients done by Falangola el. at. They divided the subjects into three groups: control, 
MCI and AlzD patients with no gender and age difference. All kurtosis metrics of AlzD patients 
and MCI are decreased in the anterior corona radiate compared with controls. RK and MK 
were decreased in temporal oval, segmental temporal and the genu of the corpus callosum, 
while RK was decreased in segmented prefrontal white matter of AlzD patients compared to 
controls. In comparison of MCI group with the controls, MK and RK were decreased in the 
prefrontal oval. These findings can provide evidence that significant changes in kurtosis are 
capable to differentiate the early changes as in MCI as well as in the late stage of AlzD 
compared to controls (70). However, a different study done by Wang, Guo et al. 2015, also 
divided the subjects into three groups control, MCI and AlzD patients with gender and age as 
the main difference between them. This study focused on hippocampus and a significant 
decrease of MK in MCI and AlzD patients was identified, also the lowest significant value was 
exhibited in AlzD patients. The authors explained these findings as results of the progression 
from normal brain tissue to MCI and then to AlzD. AlzD brain pathology is associated with 
the decrease in the structural complexity of the brain tissue and the lower tissue complexity the 
lower MK value (71). Furthermore, Gong et al. (2013), found kurtosis changes in four cerebral 
lobes. RK and MK were significantly decreased in WM of the parietal lobe. An increase of AK 
was found in the WM of the occipital lobe. No parameter was found to be significantly different 
between two groups in GM or WM of frontal and temporal lobes. This decrease in kurtosis in 
several cerebral lobes suggest that GM damage may expand from the temporal lobe to the 
Parieto-occipital association cortices as well as to frontal lobe, due to loss of neuronal cell 
bodies, synapse and dendrites (72). In conclusion, based on the previous reports, most of the 
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studies were able to detect the difference between MCI, AlzD and controls in different brain 
regions. Interestingly, all these studies were also able to differentiate between AlzD and MCI 
using DKI, which shows that DKI may be a useful biomarker for early stage of AlzD. However, 
more investigation and data are needed to prove this hypothesis.  
 
Preclinical studies 
In case of preclinical AlzD research there is only one study available which evaluated the 
accumulation of amyloid-β in a co-expressed KM670/671NL mutated amyloid precursor 
protein and L166P mutated presenilin 1 (APP/PS1) transgenic mice (73). This animal model is 
co-expressed by mutated presenilin 1 and mutated amyloid precursor protein which is believed 
to be a hallmark of AlzD. Using DKI and comparing it with the histopathological results, this 
study showed an increase in all kurtosis matrices in thalamus and cortex. This results 
corresponded to a histopathological evaluation of amyloid-β accumulation which may increase 
the microstructural complexity and neuronal loss of the brain tissue (74, 75) which can explain 
the kurtosis increase in both regions. The limitation of this study is the lack of evidence of 
causal relationship between kurtosis and amyloid-β accumulation. However, this report is a 
start for further investigation in animal models which could provide a better understanding the 
exact link between the AlzD-like pathology and kurtosis changes. Longitudinal study with DKI 
might prove if DKI is effective in evaluation of the pathology progression in this animal model. 
 
Huntington’s disease (HD) 
Huntington’s disease (HD) is a neurodegenerative genetic disorder and is one of several 
trinucleotides repeat disorders. Huntington protein is coded by a gene called huntingtin gene, 
a repeated part of this gene in called trinucleotide repeat. Normally it varies in length between 
individuals, but when this repetition reaches certain point it alters huntingtin protein to form a 
mutilated protein called mutilated huntingtin protein, these mutilated proteins leads to a 
pathological change that causes HD (76). A large set of data studied the specific function of 
mutilated huntingtin protein at microstructural level and its pathological effect that causes HD.  
To date, there is no curative treatment for HD. However, a reliable non-invasive biomarker 
would allow us to follow the progression of HD and give us a better chance to develop an 
effective therapy. As DKI proved the sensitivity toward the pathological progression of PD and 
AlzD, it could be a useful biomarker to predict the development of HD as well. Unfortunately, 
only few preclinical studies where done using DKI with no clinical data up till now. 
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Preclinical studies 
There are two HD preclinical studies using tgHD transgenic rat model expresses a truncated 
huntingtin cDNA fragment that encodes 51 CAG repeats (77). This model is characterized by 
a pathological brain progression similar to HD together with motor abnormalities. The first 
study found an increase of RK in striatum and external capsule and suggested that this changes 
in the striatum may appear due to a high degree of diffusion complexity and restriction, while 
the changes in the external capsule may reflect fiber composition or cell permeability (78). The 
second study used newborn animals of both genders and DKI was assessed at postnatal days 
15 and 30 in WM as well as GM. All kurtosis metrics were increased in the postnatal day 30 
compared to day 15 in cortex, caudate putamen, corpus callosum and anterior commissure 
while in external capsule only MK and RK were increased. AK increased in caudate putamen 
in tgHD. These studies reported a novel finding in both aged and newborn transgenic rats of 
HD. These observations in diffusion characteristics provided us evidence that DKI is sensitive 
toward brain developmental abnormalities in distinct white and gray matter structures, 
associated with HD.  
 
Conclusion 
The importance of early diagnosis in neurodegeneration is of paramount importance for the 
future development of neuroprotective treatments. Furthermore, such approach helps in better 
understanding of the mechanisms which underlay the pathology. Based on the studies we 
reviewed, changes in DKI matrices reflects the structural complexity which may occur due to 
neuroinflammation such as immune activation and protein accumulation. Additionally, DKI 
showed a remarkable Effect in detecting the changes in GM over DTI in neurodegeneration 
diseases. This could bring the importance of DKI in as an early biomarker neurodegenerative 
diseases. Despite this, more data is needed to prove the validity of DKI as an early biomarker.  
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Figure legends 
 
Figure 1 
Illustration of diffusion displacement probability distribution with different degrees of kurtosis, 
where K = 0 is a Gaussian and K > 0 is non-Gaussian water distribution. Mathematically K < 
0 is possible, but multicompartment diffusion models and empirical evidence indicate that 
kurtosis is always nonnegative (19). 
 
Figure 2 
Scheme of diffusion MR using spin echo sequence and illustration of the physical quantities of 
the b-value. Received signal from stationery molecules are unaffected, while free water 
molecules move into different locations, diphase and consequently the signal is lost. 
 
Figure 3 
Schematic representation of diffusion tensor ellipsoid (e1, e2, e3 are eigenvectors; λ1, λ2, λ3 are 
eigenvalues) and distribution of kurtosis.  
 
Figure 4 
Illustration of MR signal loss curve as a function of b-value for Gaussian (DTI) and non-
Gaussian (DKI) models of water diffusion in brain.  
 
